Abstract
The report of the results of the first generation taxane trials has made evident that these drugs should play a key role in the adjuvant treatment of node-positive operable breast cancer. Although direct comparisons among the different taxane regimens is still lacking, the American AC-paclitaxel dose-dense regimen, the TAC regimen, the French FEC-docetaxel and the Spanish FEC-paclitaxel regimens seem to offer the best results. The TC regimen (docetaxel-cyclophosphamide) is another option, particularly in patients at high risk for cardiac toxicity. Trastuzumab should now be part of the standard adjuvant treatment of HER-2neu positive breast cancer, probably administered in combination with a taxane regimen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
